MTAP Fact Sheet June 2007

MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a larger scale manufacturing process for a limited time until this manufacturing scale is approved by the FDA.  Patients enrolled in MTAP...

Genzyme Pompe Program Update—June 2007

Genzyme would like to take this opportunity to provide a brief update to the Pompe patient community regarding the US supply of Myozyme® (alglucosidase alfa).  As planned, Genzyme submitted the necessary documentation to the FDA this month for the licensure of the...